10X Historical Financial Ratios

TXG Stock

USD 15.90 0.42 2.71%

10X Genomics is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 6.64, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.28 will help investors to properly organize and evaluate 10X Genomics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

About 10X Financial Ratios Analysis

10X GenomicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate 10X Genomics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on 10X financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across 10X Genomics history.

10X Genomics Financial Ratios Chart

At this time, 10X Genomics' Stock Based Compensation To Revenue is most likely to increase slightly in the upcoming years. The 10X Genomics' current Capex To Depreciation is estimated to increase to 2.22, while Days Sales Outstanding is projected to decrease to 52.06.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover Return On Tangible Assets

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing 10X Genomics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on 10X Genomics sales, a figure that is much harder to manipulate than other 10X Genomics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Return On Tangible Assets

A profitability metric that measures a company's ability to generate earnings from its tangible assets.

Most ratios from 10X Genomics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into 10X Genomics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.At this time, 10X Genomics' Stock Based Compensation To Revenue is most likely to increase slightly in the upcoming years. The 10X Genomics' current Capex To Depreciation is estimated to increase to 2.22, while Days Sales Outstanding is projected to decrease to 52.06.

	2021	2022	2023	2024 (projected)
Payables Turnover	4.27	5.57	13.31	13.97
Days Of Inventory On Hand	295.41	247.49	128.47	140.12

Payables Turnover Days Of Inventory On Hand

10X Genomics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.84	-0.32	0.56	0.31	0.02	0.26	0.84	1.0	0.0	-0.39	-0.33	-0.16	0.43	0.49	0.42	0.33	-0.4	0.03	-0.22	-0.16	-0.52	-0.08	-0.72	-0.39	-0.46
Ptb Ratio	0.84		-0.45	0.86	0.31	0.19	0.59	1.0	0.84	0.09	-0.67	-0.14	-0.07	0.39	0.69	0.72	0.43	-0.62	-0.28	-0.53	-0.42	-0.84	-0.43	-0.79	-0.62	-0.57
Days Sales Outstanding	-0.32	-0.45		-0.6	-0.44	-0.38	-0.59	-0.45	-0.3	-0.34	0.46	-0.52	-0.12	0.34	-0.46	-0.26	-0.86	0.16	0.34	-0.04	0.82	0.49	0.77	0.42	0.19	0.27
Book Value Per Share	0.56	0.86	-0.6		0.53	0.55	0.74	0.86	0.55	0.43	-0.89	0.02	0.24	0.23	0.72	0.81	0.54	-0.49	-0.43	-0.53	-0.63	-0.85	-0.73	-0.84	-0.5	-0.41
Free Cash Flow Yield	0.31	0.31	-0.44	0.53		0.91	0.15	0.31	0.3	0.94	-0.68	-0.22	0.8	0.21	0.24	0.22	0.23	-0.31	-0.24	-0.18	-0.45	-0.1	-0.39	-0.53	-0.31	-0.34
Operating Cash Flow Per Share	0.02	0.19	-0.38	0.55	0.91		0.33	0.19	0.02	0.98	-0.69	-0.15	0.92	0.21	0.13	0.37	0.22	-0.27	-0.25	-0.27	-0.52	-0.09	-0.53	-0.38	-0.27	-0.32
Capex To Depreciation	0.26	0.59	-0.59	0.74	0.15	0.33		0.59	0.24	0.14	-0.42	0.27	0.14	0.1	0.22	0.84	0.78	-0.14	0.04	-0.2	-0.78	-0.58	-0.83	-0.34	-0.15	-0.47
Pb Ratio	0.84	1.0	-0.45	0.86	0.31	0.19	0.59		0.84	0.09	-0.67	-0.14	-0.07	0.39	0.69	0.72	0.43	-0.62	-0.28	-0.53	-0.42	-0.84	-0.43	-0.79	-0.62	-0.57
Ev To Sales	1.0	0.84	-0.3	0.55	0.3	0.02	0.24	0.84		-0.01	-0.39	-0.35	-0.16	0.45	0.49	0.42	0.31	-0.41	0.03	-0.24	-0.14	-0.52	-0.06	-0.72	-0.41	-0.46
Free Cash Flow Per Share	0.0	0.09	-0.34	0.43	0.94	0.98	0.14	0.09	-0.01		-0.64	-0.17	0.92	0.15	0.11	0.2	0.12	-0.23	-0.27	-0.2	-0.42	0.02	-0.41	-0.35	-0.24	-0.23
Roic	-0.39	-0.67	0.46	-0.89	-0.68	-0.69	-0.42	-0.67	-0.39	-0.64		0.12	-0.4	-0.21	-0.77	-0.59	-0.23	0.53	0.66	0.62	0.4	0.73	0.54	0.86	0.55	0.21
Inventory Turnover	-0.33	-0.14	-0.52	0.02	-0.22	-0.15	0.27	-0.14	-0.35	-0.17	0.12		-0.31	-0.91	0.14	-0.23	0.58	0.39	-0.24	0.49	-0.56	-0.18	-0.59	0.15	0.37	0.3
Net Income Per Share	-0.16	-0.07	-0.12	0.24	0.8	0.92	0.14	-0.07	-0.16	0.92	-0.4	-0.31		0.34	-0.23	0.22	-0.01	-0.22	-0.01	-0.21	-0.32	0.26	-0.26	-0.05	-0.22	-0.37
Days Of Inventory On Hand	0.43	0.39	0.34	0.23	0.21	0.21	0.1	0.39	0.45	0.15	-0.21	-0.91	0.34		-0.11	0.54	-0.33	-0.55	0.27	-0.63	0.28	-0.02	0.33	-0.2	-0.53	-0.6
Payables Turnover	0.49	0.69	-0.46	0.72	0.24	0.13	0.22	0.69	0.49	0.11	-0.77	0.14	-0.23	-0.11		0.3	0.22	-0.44	-0.8	-0.47	-0.2	-0.89	-0.36	-0.85	-0.46	0.07
Capex To Revenue	0.42	0.72	-0.26	0.81	0.22	0.37	0.84	0.72	0.42	0.2	-0.59	-0.23	0.22	0.54	0.3		0.39	-0.38	0.0	-0.56	-0.43	-0.62	-0.53	-0.52	-0.38	-0.53
Cash Per Share	0.33	0.43	-0.86	0.54	0.23	0.22	0.78	0.43	0.31	0.12	-0.23	0.58	-0.01	-0.33	0.22	0.39		0.14	0.06	0.29	-0.88	-0.41	-0.83	-0.3	0.12	-0.27
Pocfratio	-0.4	-0.62	0.16	-0.49	-0.31	-0.27	-0.14	-0.62	-0.41	-0.23	0.53	0.39	-0.22	-0.55	-0.44	-0.38	0.14		0.51	0.87	0.07	0.47	0.01	0.36	1.0	0.69
Interest Coverage	0.03	-0.28	0.34	-0.43	-0.24	-0.25	0.04	-0.28	0.03	-0.27	0.66	-0.24	-0.01	0.27	-0.8	0.0	0.06	0.51		0.52	0.13	0.61	0.26	0.46	0.53	-0.14
Capex To Operating Cash Flow	-0.22	-0.53	-0.04	-0.53	-0.18	-0.27	-0.2	-0.53	-0.24	-0.2	0.62	0.49	-0.21	-0.63	-0.47	-0.56	0.29	0.87	0.52		-0.09	0.54	0.0	0.4	0.87	0.45
Pfcf Ratio	-0.16	-0.42	0.82	-0.63	-0.45	-0.52	-0.78	-0.42	-0.14	-0.42	0.4	-0.56	-0.32	0.28	-0.2	-0.43	-0.88	0.07	0.13	-0.09		0.39	0.94	0.27	0.09	0.43
Days Payables Outstanding	-0.52	-0.84	0.49	-0.85	-0.1	-0.09	-0.58	-0.84	-0.52	0.02	0.73	-0.18	0.26	-0.02	-0.89	-0.62	-0.41	0.47	0.61	0.54	0.39		0.54	0.78	0.49	0.17
Income Quality	-0.08	-0.43	0.77	-0.73	-0.39	-0.53	-0.83	-0.43	-0.06	-0.41	0.54	-0.59	-0.26	0.33	-0.36	-0.53	-0.83	0.01	0.26	0.0	0.94	0.54		0.4	0.03	0.22
Roe	-0.72	-0.79	0.42	-0.84	-0.53	-0.38	-0.34	-0.79	-0.72	-0.35	0.86	0.15	-0.05	-0.2	-0.85	-0.52	-0.3	0.36	0.46	0.4	0.27	0.78	0.4		0.37	0.09
Ev To Operating Cash Flow	-0.39	-0.62	0.19	-0.5	-0.31	-0.27	-0.15	-0.62	-0.41	-0.24	0.55	0.37	-0.22	-0.53	-0.46	-0.38	0.12	1.0	0.53	0.87	0.09	0.49	0.03	0.37		0.68
Pe Ratio	-0.46	-0.57	0.27	-0.41	-0.34	-0.32	-0.47	-0.57	-0.46	-0.23	0.21	0.3	-0.37	-0.6	0.07	-0.53	-0.27	0.69	-0.14	0.45	0.43	0.17	0.22	0.09	0.68

Click cells to compare fundamentals

10X Genomics Account Relationship Matchups

10X Genomics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	12.11	47.93	33.51	8.03	10.6	14.35
Ptb Ratio	7.09	19.38	20.11	5.15	8.85	5.94
Days Sales Outstanding	49.54	62.54	63.44	73.66	67.74	52.06
Book Value Per Share	10.75	7.31	7.41	7.08	6.32	6.64
Free Cash Flow Yield	(0.002733)	(0.0179)	(0.007462)	(0.0398)	(0.009871)	(0.0104)
Operating Cash Flow Per Share	0.89	(2.15)	(0.19)	(0.3)	(0.13)	(0.14)
Stock Based Compensation To Revenue	0.0542	0.16	0.2	0.26	0.27	0.28
Capex To Depreciation	6.05	2.02	3.58	3.99	1.14	2.22
Pb Ratio	7.09	19.38	20.11	5.15	8.85	5.94
Ev To Sales	10.51	45.92	32.48	7.79	10.17	13.66
Free Cash Flow Per Share	(0.21)	(2.53)	(1.11)	(1.45)	(0.55)	(0.58)
Roic	(0.0651)	(0.11)	(0.0638)	(0.19)	(0.33)	(0.31)
Inventory Turnover	4.0	1.95	1.24	1.47	2.84	2.67
Net Income Per Share	(0.8)	(5.37)	(0.53)	(1.46)	(2.18)	(2.29)
Days Of Inventory On Hand	91.32	187.03	295.41	247.49	128.47	140.12
Payables Turnover	4.68	12.42	4.27	5.57	13.31	13.97
Sales General And Administrative To Revenue	0.53	0.67	0.52	0.57	0.55	0.64
Research And Ddevelopement To Revenue	0.32	0.34	0.41	0.43	0.51	0.44
Capex To Revenue	0.17	0.13	0.21	0.25	0.08	0.1
Cash Per Share	10.86	6.56	5.32	3.78	3.32	6.11
Pocfratio	86.02	(65.73)	(769.07)	(123.46)	(431.44)	(409.87)
Interest Coverage	(9.44)	(50.73)	(61.1)	(352.82)	(8.0K)	(7.6K)
Capex To Operating Cash Flow	1.24	(0.18)	(4.74)	(3.92)	(3.26)	(3.42)
Pfcf Ratio	(365.92)	(55.89)	(134.02)	(25.1)	(101.3)	(106.37)
Days Payables Outstanding	77.91	29.4	85.48	65.49	27.43	26.06
Income Quality	(1.11)	0.4	0.37	0.2	0.0596	0.0566
Roe	(0.0744)	(0.73)	(0.0712)	(0.21)	(0.34)	(0.33)
Ev To Operating Cash Flow	74.63	(62.98)	(745.42)	(119.75)	(414.07)	(434.77)
Pe Ratio	(95.31)	(26.39)	(282.32)	(24.99)	(25.7)	(26.99)
Return On Tangible Assets	(0.0536)	(0.6)	(0.0589)	(0.17)	(0.27)	(0.28)
Ev To Free Cash Flow	(317.46)	(53.54)	(129.9)	(24.35)	(97.23)	(102.09)
Earnings Yield	(0.0105)	(0.0379)	(0.003542)	(0.04)	(0.0389)	(0.0409)
Net Debt To E B I T D A	18.88	1.17	20.55	0.97	1.29	1.22
Current Ratio	7.63	6.56	6.77	4.85	4.69	4.21
Tangible Book Value Per Share	10.18	7.09	7.14	6.84	6.14	6.45
Receivables Turnover	7.37	5.84	5.75	4.96	5.39	6.26
Graham Number	13.91	29.7	9.38	15.24	17.6	25.2
Shareholders Equity Per Share	10.75	7.31	7.41	7.08	6.32	6.64
Debt To Equity	0.0707	0.0852	0.1	0.12	0.13	0.14

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:

How To Invest In 10X

Details

Is 10X Stock a good investment?

Details

What is 10X Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.52)

Revenue Per Share

5.261

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.11)

Return On Equity

(0.25)

The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

10X Historical Financial Ratios

About 10X Financial Ratios Analysis

10X Genomics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

Return On Tangible Assets

10X Genomics fundamentals Correlations

10X Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

10X Genomics fundamentals Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Free Cash Flow Per Share	+ 0.98	Operating Cash Flow Per Share
Free Cash Flow Per Share	+ 0.94	Free Cash Flow Yield
Income Quality	+ 0.94	Pfcf Ratio

Days Of Inventory On Hand	- 0.91	Inventory Turnover
Days Payables Outstanding	- 0.89	Payables Turnover
Roic	- 0.89	Book Value Per Share
Pfcf Ratio	- 0.88	Cash Per Share
Cash Per Share	- 0.86	Days Sales Outstanding
Roe	- 0.85	Payables Turnover